COMTESS

This brand name is authorized in Austria, Croatia, Estonia, Finland, Ireland, Lithuania, Netherlands, Poland, Romania, UK.

Active ingredients

The drug COMTESS contains one active pharmaceutical ingredient (API):

1	Entacapone UNII 4975G9NM6T - ENTACAPONE
	Entacapone belongs to a new therapeutic class, catechol-O-methyl transferase (COMT) inhibitors. It is a reversible, specific, and mainly peripherally acting COMT inhibitor designed for concomitant administration with levodopa preparations. Entacapone prolongs the clinical response to levodopa.
	Read more about Entacapone

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
N04BX02	Entacapone	N Nervous system → N04 Anti-parkinson drugs → N04B Dopaminergic agents → N04BX Other dopaminergic agents
Discover more medicines within N04BX02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1030273, 1064595, 1064607, 1363485
FI	Lääkealan turvallisuus- ja kehittämiskeskus	432229, 433250
GB	Medicines & Healthcare Products Regulatory Agency	22297, 22298
IE	Health Products Regulatory Authority	18221
LT	Valstybinė vaistų kontrolės tarnyba	1002975, 1008049, 1016715, 1028312
NL	Z-Index G-Standaard, PRK	52035
PL	Rejestru Produktów Leczniczych	100160580
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W51543001, W51543002, W51543003, W51543004